期刊
ARTHRITIS & RHEUMATOLOGY
卷 67, 期 3, 页码 797-808出版社
WILEY-BLACKWELL
DOI: 10.1002/art.38966
关键词
-
类别
资金
- National Health and Medical Research Council (NHMRC) of Australia program [1016647, 1016701, 1037321]
- Juvenile Diabetes Research Foundation
- Rebecca L. Cooper Foundation
- Leukemia & Lymphoma Society Special Center of Research [7001-13]
- NHMRC Independent Research Institutes Infrastructure Support Scheme [361646]
- Victorian State Government Operational Infrastructure Support
- Australian Government
- [637324]
- [1007703]
- [1021374]
- [104610]
- [1043414]
- [1043149]
- [1020363]
Objective. Interferon- (IFN alpha)-producing plasmacytoid dendritic cells (PDCs) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). IFN-related genes are highlighted among SLE susceptibility alleles and are characteristically expressed in the blood of patients with SLE, while in mouse models of lupus, PDC numbers and IFN production are increased. This study was undertaken to investigate the effects of inhibitors that selectively target different antiapoptotic molecules on the survival of PDCs. Methods. PDC numbers, in vitro survival, and expression of antiapoptotic molecules were evaluated in lupus-prone (NZB x NZW)F1 (NZB/NZW) mice. The impact of Bcl-2 antagonists and glucocorticoids on PDCs was evaluated in vitro and in vivo. IFN production by NZB/NZW mice was evaluated before and after treatment with Bcl-2 antagonists. Results. PDCs, but not lymphoid tissue-resident conventional DCs, largely relied on the antiapoptotic protein Bcl-2 for survival. The enlarged PDC compartment in NZB/NZW mice was associated with selectively prolonged survival and increased Bcl-2 transcription. Functionally, this resulted in enhanced production of IFN. Bcl-2 inhibitors selectively killed mouse and human PDCs, including PDCs from SLE patients, but not conventional DCs, dampened IFN production by PDCs, and synergized with glucocorticoids to kill activated PDCs. Conclusion. Enhanced PDC survival is a likely contributing factor to enhanced IFN production by lupus PDCs. Bcl-2 antagonists potently and selectively kill PDCs and reduce IFN alpha production. Thus, we believe that they are attractive candidates for treating PDC-associated diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据